{
  "docId": "019dd923-622c-750b-8b9a-2a2468219173",
  "docSlug": "ce565b841c40",
  "documentTitle": "Nevro Corp. (NVRO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Kir Kahlon",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2021-01-07 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 79,
  "pageCount": 239,
  "prevPage": 78,
  "nextPage": 80,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": "Uses testimonials to contradict the company's marketing claims.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-2a2468219173/79",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173#slide-79",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Nevro had supposedly found the holy grail: eliminating pain versus masking it with paresthesia.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b33c-9c37cc0c1cd4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.88,
        "x": 0.06,
        "y": 0.13
      },
      "kind": "paragraph",
      "text": "Nevro had supposedly found the holy grail: eliminating pain versus masking it with paresthesia. Traditional stimulators are implanted with the patients awake to enable paresthesia-mapping: the physician adjusts the placement of stimulator leads along the spine in a trial-and-error process until the patient reports tingling that overlaps with the area of pain. Nevro touted that it eliminated the need for \"paresthesia-mapping,\" but quickly discovered upon launch that a large percentage of doctors and patients strongly preferred paresthesia. Comments from a KOL and two former employees are representative.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0eb44a98-cc8c-433b-a242-1486246a238d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.88,
        "x": 0.06,
        "y": 0.76
      },
      "kind": "quote",
      "text": "If the leads move even a little bit the Nevro reps get lost and they don't know where to program because there's no buzzing or tingling, no paresthesia. So they don't know what to do. They're programming blind.",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7ff8b85b-0fba-48cc-82fe-086a1c096c99",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.88,
        "x": 0.06,
        "y": 0.55
      },
      "kind": "quote",
      "text": "The HF10 results don't pan out over time, correct. Again, that's my personal opinion. It's the reason Omnia is out. A lot of people wanted the paresthesia. Even right from the start, probably 50% of the doctors that I came across wanted paresthesia as an option for patients. They were saying, what if a patient wants it? We'd say, no, no, we have to follow the evidence and we can only do it this way.",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a9060974-d5aa-4112-aad8-df987e079e24",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.88,
        "x": 0.06,
        "y": 0.35
      },
      "kind": "quote",
      "text": "Nevro didn't want the patient to feel paresthesia, but what you'll find is that they crave the paresthesia. Once they feel it, they think that that's the indication of whether the device is working or not. You can't just get rid of paresthesia unilaterally and say it's a great thing because there are definitely reasons for it.",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f333eb13-5ad0-4f3c-84de-f8d6297f055a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "\"Nevro didn’t want the patient to feel paresthesia, but what you’ll find is that they crave the paresthesia. Once they feel it, they think that that’s the indication of whether the device is working or not. You can’t just get rid of paresthesia unilaterally and say it's a great thing because there are definitely reasons for it.\" — High volume implanter/KOL; \"The HF10 results don’t pan out over time, correct. Again, that’s my personal opinion. It's the reason Omnia is out. A lot of people wanted the paresthesia. Even right from the start, probably 50% of the doctors that I came across wanted paresthesia as an option for patients. They were saying, what if a patient wants it? We’d say, no, no, we have to follow the evidence and we can only do it this way.\" — Former Nevro territory manager; \"If the leads move even a little bit the Nevro reps get lost and they don’t know where to program because there’s no buzzing or tingling, no paresthesia. So they don’t know what to do. They’re programming blind.\" — High volume implanter/KOL",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b33c-a2eff9c8a51d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.2,
        "x": 0.06,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "Source: Consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "38d292cc-3e7c-4252-9f65-d45837b0c811",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.6,
        "x": 0.06,
        "y": 0.09
      },
      "kind": "title",
      "text": "5. High frequency is Nevro's fatal flaw and dooms any turnaround",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "538bff10-bd34-4920-898f-f1ec918da35d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.35,
        "x": 0.06,
        "y": 0.04
      },
      "kind": "title",
      "text": "Scorpion Capital | Nevro (NYSE: NVRO)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "14994901-4c40-4c9c-9341-c29e741fe08e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 150,
      "from": 51,
      "beatId": "903c076a-f368-4ca1-844c-277874c1afb2",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "The Victory",
      "beatSlug": "overcoming-monster-the-victory",
      "evidence": "The deck presents a conclusion that Nevro's problems are insurmountable",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}